A multicentre, randomized, double-blind, placebo-controlled, parallel-group study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.
A study for patients with ulcerative colitis using study drug tofacitinib as an induction therapy
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAN5852
U.S. Govt. ID: NCT01465763
Contact: Simon Lichtiger: 212-305-1021 / sl3687@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if a new investigational drug, called tofacitinib (also known as tofacitinib citrate or CP-690,550), can help people with Ulcer Colitis (UC). The purpose of this research study is to compare the effects of tofacitinib to a placebo in patients with Ulcer Colitis (UC). A placebo looks like the study drug but does not contain any drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything. If you choose to participate in this study, you will have a 4 in 5 (80%) chance of receiving tofacitinib and a 1 in 5 (20%) chance of receiving placebo.
This study is closed
Investigator
Simon Lichtiger, MD
Do You Qualify?
Do you have a confirmed diagnosis of UC? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Simon Lichtiger
sl3687@cumc.columbia.edu
212-305-1021
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE